BTOG 2019 | Checkpoint inhibition in mesothelioma: the CONFIRM trial

Dean Fennell

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, gives an overview of the CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM; NCT03063450) trial, which is investigating nivolumab. This video was recorded at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.

Share this video